This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Feb;108(1):69-70.

doi: 10.1007/s00063-012-0206-y.

[Lost in translation? On the effectiveness and efficacy of drotrecogin alfa (recombinant human activated protein C)]

[Article in German]

H Gerlach¹

Affiliations

Affiliation

¹ Klinik für Anästhesie, operative Intensivmedizin und Schmerztherapie, Vivantes-Klinikum Neukölln, Rudower Strasse 48, Berlin, Germany. herwig.gerlach@vivantes.de

PMID: 23263456
DOI: 10.1007/s00063-012-0206-y

Comment

[Lost in translation? On the effectiveness and efficacy of drotrecogin alfa (recombinant human activated protein C)]

[Article in German]

H Gerlach. Med Klin Intensivmed Notfmed. 2013 Feb.

. 2013 Feb;108(1):69-70.

doi: 10.1007/s00063-012-0206-y.

Author

H Gerlach¹

Affiliation

¹ Klinik für Anästhesie, operative Intensivmedizin und Schmerztherapie, Vivantes-Klinikum Neukölln, Rudower Strasse 48, Berlin, Germany. herwig.gerlach@vivantes.de

PMID: 23263456
DOI: 10.1007/s00063-012-0206-y

No abstract available

PubMed Disclaimer

Comment on

Drotrecogin alfa (activated) in adults with septic shock.
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Ranieri VM, et al. N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22. N Engl J Med. 2012. PMID: 22616830 Clinical Trial.

Similar articles

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC, LaRosa SP. Kalil AC, et al. Lancet Infect Dis. 2012 Sep;12(9):678-86. doi: 10.1016/S1473-3099(12)70157-3. Epub 2012 Jul 17. Lancet Infect Dis. 2012. PMID: 22809883
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Bernard GR, et al. N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001. N Engl J Med. 2001. PMID: 11236773 Clinical Trial.
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators. Angus DC, et al. Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001. Crit Care Med. 2003. PMID: 12544986 Clinical Trial.
Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D. De Backer D. Drug Saf. 2007;30(11):995-1010. doi: 10.2165/00002018-200730110-00002. Drug Saf. 2007. PMID: 17973539 Review.
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C, Matthews SJ. McCoy C, et al. Clin Ther. 2003 Feb;25(2):396-421. doi: 10.1016/s0149-2918(03)80086-3. Clin Ther. 2003. PMID: 12749504 Review.

See all similar articles

References

1. Crit Care Med. 2012 May;40(5):1417-26 - PubMed
1. Lancet Infect Dis. 2012 Sep;12(9):678-86 - PubMed
1. Crit Care Med. 2012 Nov;40(11):2974-81 - PubMed
1. Minerva Anestesiol. 2013 Jan;79(1):33-43 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer